Luminex (NASDAQ: LMNX) is one of 79 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its rivals? We will compare Luminex to related companies based on the strength of its earnings, dividends, analyst recommendations, institutional ownership, profitability, valuation and risk.
Luminex pays an annual dividend of $0.24 per share and has a dividend yield of 1.2%. Luminex pays out 36.4% of its earnings in the form of a dividend. As a group, “Advanced Medical Equipment & Technology” companies pay a dividend yield of 0.8% and pay out 25.8% of their earnings in the form of a dividend.
This is a summary of current recommendations and price targets for Luminex and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Luminex currently has a consensus target price of $20.50, suggesting a potential downside of 1.11%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 4.32%. Given Luminex’s higher probable upside, equities analysts plainly believe Luminex is more favorable than its rivals.
Institutional and Insider Ownership
79.2% of Luminex shares are held by institutional investors. Comparatively, 51.8% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 6.9% of Luminex shares are held by insiders. Comparatively, 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares Luminex and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Luminex has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, Luminex’s rivals have a beta of 1.48, suggesting that their average share price is 48% more volatile than the S&P 500.
Earnings and Valuation
This table compares Luminex and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Luminex||$270.64 million||$13.81 million||31.41|
|Luminex Competitors||$2.14 billion||$234.27 million||-95.69|
Luminex’s rivals have higher revenue and earnings than Luminex. Luminex is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Luminex rivals beat Luminex on 8 of the 15 factors compared.
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The Company has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories.
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.